Earlier this month, Korro Bio announced a collaboration with Novo Nordisk (NYSE:NVO) to develop a pair of therapeutic ...

Lexaria's strategy is to continue developing and optimizing our wholly-owned DehydraTECH™ drug delivery platform for application in the GLP-1 space, positioning it as a 'must-have' technology for ...

Some other companies using ADAR enzymes to perform RNA editing are Korro Bio for AATD and Parkinson’s disease ... from large ...